• Granules
  • Salofalk^® 500mg, 1g, 1.5g & 3g gastro-resistant, modified release granule sachets (First- line for all new UC patients, with 1.5g or 3g sachets most cost- effective).
  • Pentasa^® 1g, 2g & 4g modified-release granule sachets (Salisbury & Swindon ONLY).
• Tablets
  • Octasa^® 400mg & 800mg MR tablets (Second- line).
  • Asacol MR^® 400mg & 800mg MR tablets (Existing patients only).
  • Salofalk^® 250mg, 500mg & 1g gastro-resistant tablets.
  • Pentasa^® 500mg & 1g MR tablets (Salisbury & Swindon ONLY).
  • Pentasa^® 500mg MR tablets (BaNES - Existing patient only).

• Suppositories
  • Salofalk^® 500mg & 1g suppositories (First-line).
  • Pentasa^® 1g suppositoires.
• Foam Enemas
  • Salofalk^® 1g/application foam enema. 
• Liquid Enemas
  • Salofalk^® 2g/59ml enema (First- line).
  • Pentasa^® 1g/100ml enema.

Please note: Asacol suppositories and foam enema have been removed from formulary, as they have been discontinued (2018). See link below for May 2020 supply disruption notice for rectal 5-ASA preparations.

• 500mg tablets.
• 500mg EN tablets.
• Please note: Sulphasalazine is not generally recommended for use in new patients, but may be useful for patients with concomitant arthritis.

• 750mg capsules.
• Please note: Balsalazide is indicated for the treatment of mild to moderate ulcerative colitis and maintenace of remission, but should ONLY be prescribed for patients not responding to other aminosalicylates. 

• 3mg gastro-resistant capsules.
• Please note: Budenofalk capsules are available for use for their licensed indications of:
  • induction of remission in patients with mild to moderate Crohn's disease affecting the ileum and/or ascending colon,
  • induction of remmission in patients with active collagenous colitis.
• Please prescribe BY BRAND. 

• 9mg prolonged-release tablets.
• Note not on formulary at SFT.
• For induction of remission in patients with mild to moderate ulcerative colitis, where 5-ASA treatment is not sufficient.
• Please prescribe BY BRAND.

• 1mg oro-dispersible tablets.
• For treatment of eosinophlic oesophagitis.
• Please prescribe BY BRAND.

• 2mg per actuation white foam, 1 canister (14 days treatment).
• Please note: Budesonide foam enema is ONLY indicated for use second line in patients unable to use / tolerate Colifoam^® enema.

• 20mg retention enema.
• 5mg suppositories.
• Please note: Prednisolone foam enema has been removed from formulary as it is prohibitively expensive.

•  - BaNES & Wiltshire patients
•  - GWH - Swindon DAWN patients.
• 25mg & 50mg tablets.
• Please refer to our DMARD Shared Care and Monitoring Guidance below for further information.

•  - BaNES & Wiltshire
•  - GWH - Swindon DAWN patients. 
  Note: Only the 50mg strength tablets are included on the formulary for gastro indications in adults. The 50mg tablets are licensed but used 'off-label' for gastro indications e.g. severe ulcerative colitis and Crohn’s. 10mg strength tablets are unlicensed specials and prohibitively expensive when sourced in primary care. Alternate dosing using 50mg/100mg should be considered where daily doses between 50 and 100mgs are required for adults. For use in children see paediatric chapter.
  
• Please refer to our DMARD Shared Care and Monitoring Guidance below for further information.

•  - BaNES, Salisbury & Swindon (except Swindon patients monitored via the DAWN system and provided with prescriptions by GWH).
•  - GWH - Swindon DAWN patients.
• 2.5mg tablets ONLY.
• Please note: Methotrexate is administered weekly.
• Please refer to our DMARD Shared Care and Monitoring Guidance for your respective locality for further information.

• 10mg, 25mg, 50mg & 100mg capsules.
• 250mg in 5ml ampoules for intravenous infusion.
• Please refer to our DMARD Shared Care and Monitoring Guidance below for monitoring information (not applicable to GWH gastroenterology).

• 40mg pre-filled pens or pre-filled syringes.
• Prescribe BY BRAND. Biosimilar first-line option. Imraldi^® first-line biosimilar.
• Please note: Adalimumab should be prescribed in accordance with either the BSW STP Ulcerative Colitis Biologic / Biosimilar Commissioning Pathway or the BSW STP Crohn's Disease Biologic / Biosimilar Commissioning Pathway.

• 100mg vials.
• Prescribe BY BRAND. Biosimilar first-line option.
• Please note: Infliximab should be prescribed in accordance with either the BSW STP Ulcerative Colitis Biologic / Biosimilar Commissioning Pathway or the BSW STP Crohn's Disease Biologic / Biosimilar Commissioning Pathway.

• 50mg or 100mg prefilled pens.
• 50mg or 100mg prefilled syringes.
• Please note: Golimumab should be prescribed in accordance with the BSW STP Ulcerative Colitis Biologic / Biosimilar Commissioning Pathway.

• 5mg or 10mg tablets.
• Please note: Tofacitinib should be prescribed in accordance with the BSW STP Ulcerative Colitis Biologic / Biosimilar Commissioning Pathway.

• 130mg vials.
• 45mg in 0.5ml & 90mg in 1ml pre-filled syringes.
• Please note: Ustekinumab should be prescribed in accordance with the BSW STP Crohn's Disease Biologic / Biosimilar Commissioning Pathway.

• 300mg vials.
• Please note: Vedolizumab should be prescribed in accordance with either the BSW STP Ulcerative Colitis Biologic / Biosimilar Commissioning Pathway or the BSW STP Crohn's Disease Biologic / Biosimilar Commissioning Pathway.